RESUMO
Corcept Therapeutics Inc is developing mifepristone (as C-1073, Corlux), an orally available progesterone and glucocorticoid antagonist originally launched as an abortifacient by Aventis Pharma AG, for the potential treatment of the psychotic features of psychotic major depression (PMD) and for Alzheimer's disease (AD). In August 2004, a pivotal phase III trial was initiated in the US for psychotic features of PMD, a second trial began in October 2004 and these were followed by a European phase III trial in May 2005. However, in August 2006, September 2006 and March 2007, respectively, these phase III trials failed to meet their endpoints. A further phase III trial was to commence later in 2007. By August 2006, Corcept expected to file an NDA for PMD in 2007. In addition, in March 2005 a phase II study of mifepristone as a cognitive enhancer in AD was underway, and in May 2006 a proof-of-concept study in alleviating the weight gain associated with olanzapine had begun.
Assuntos
Transtorno Depressivo Maior/tratamento farmacológico , Glucocorticoides/antagonistas & inibidores , Mifepristona/uso terapêutico , Transtornos Psicóticos/tratamento farmacológico , Animais , Ensaios Clínicos Fase II como Assunto , Ensaios Clínicos Fase III como Assunto , Transtorno Depressivo Maior/complicações , Antagonistas de Hormônios/química , Antagonistas de Hormônios/farmacologia , Antagonistas de Hormônios/uso terapêutico , Humanos , Mifepristona/química , Mifepristona/farmacologia , Estrutura Molecular , Transtornos Psicóticos/complicaçõesRESUMO
OBJECTIVE: In patients with major depressive disorder (MDD), excessive sleepiness and fatigue not only are major components of the disorder, but also may occur as side effects of antidepressant therapy. In addition, sedation may be a consequence of antidepressant regimens. The novel wake-promoting agent modafinil improves wakefulness and reduces fatigue across a variety of clinical disorders. This study assessed the use of modafinil as an adjunctive treatment in patients with MDD who reported sedation related to serotonergic antidepressant therapy. METHOD: Data were collected between September 2001 and December 2003. Twenty men and women with DSM-IV-defined MDD were enrolled in this 3-week, open-label, single-center study. In addition to ongoing and stable treatment with selective serotonin reuptake inhibitors (SSRIs), clinic patients received modafinil once daily. Efficacy assessments were conducted at 1-week intervals. RESULTS: Sixteen patients (80%) completed the study. Modafinil plus SSRIs significantly improved overall depressive symptoms, as shown by reductions in mean Hamilton Rating Scale for Depression total scores (p <.001 vs. baseline). Adjunctive modafinil significantly improved subjective estimates of wakefulness on the Epworth Sleepiness Scale (p <.001, all weeks) and reduced fatigue on the Fatigue Severity Scale (p =.009). At the final visit, modafinil had improved overall health status and health-related quality of life, as shown by significant improvements in mean Medical Outcomes Study Short-Form 12-Item Health Survey total scores (p =.007) and in physical health (p =.04) and mental health (p =.006) subscores. CONCLUSION: In patients with MDD who experience sedation as a side effect of antidepressant therapy, adjunctive modafinil improved wakefulness and reduced fatigue. Modafinil plus SSRIs also improved mood and quality of life.
Assuntos
Compostos Benzidrílicos/uso terapêutico , Estimulantes do Sistema Nervoso Central/uso terapêutico , Transtorno Depressivo/tratamento farmacológico , Inibidores Seletivos de Recaptação de Serotonina/efeitos adversos , Transtornos do Sono-Vigília/induzido quimicamente , Transtornos do Sono-Vigília/tratamento farmacológico , Adulto , Transtorno Depressivo/diagnóstico , Transtorno Depressivo/psicologia , Manual Diagnóstico e Estatístico de Transtornos Mentais , Quimioterapia Combinada , Fadiga/induzido quimicamente , Fadiga/diagnóstico , Fadiga/tratamento farmacológico , Feminino , Nível de Saúde , Humanos , Masculino , Pessoa de Meia-Idade , Modafinila , Escalas de Graduação Psiquiátrica , Qualidade de Vida/psicologia , Inibidores Seletivos de Recaptação de Serotonina/uso terapêutico , Índice de Gravidade de Doença , Transtornos do Sono-Vigília/diagnóstico , Resultado do Tratamento , Vigília/efeitos dos fármacosRESUMO
Patients who are admitted to psychiatric inpatient wards often undergo a medical screening examination in the emergency department to rule out serious or underlying medical conditions that may be better treated elsewhere. Unfortunately, prior research has been conflicting on the relative merits of various screening procedures, making it difficult to implement guidelines. A systematic review of the literature was undertaken to research the current state of knowledge in medical screening procedures. Electronic searches were conducted in PubMed, MEDLINE, and the Cochrane Library for publication years 1966-2003. No restrictions were placed on language or on quality of publications. Twelve studies were found that reported specific yields of various screening procedures. Results indicate that medical history, physical examination, review of systems, and tests for orientation have relatively high yields for detecting active medical problems in patients presenting with psychiatric complaints. Routine laboratory investigations generally have a low yield for clinically significant findings. However, these should be added selectively for four groups at higher risk of serious medical conditions, i.e., the elderly, substance users, patients with no prior psychiatric history, and patients with preexisting medical disorders and/or concurrent medical complaints.
Assuntos
Doença Aguda/epidemiologia , Doença Crônica/epidemiologia , Serviço Hospitalar de Emergência , Transtornos Mentais/epidemiologia , Triagem Multifásica , Admissão do Paciente/estatística & dados numéricos , Doença Aguda/psicologia , Doença Crônica/psicologia , Comorbidade , Estudos Transversais , Testes Diagnósticos de Rotina/estatística & dados numéricos , Humanos , Achados Incidentais , Transtornos Mentais/diagnóstico , Transtornos Mentais/psicologia , Transtornos Mentais/terapiaRESUMO
In recent years, there has been an increased use of neuroleptic agents in the primary care setting. Neuroleptic malignant syndrome (NMS) is a rare complication of neuroleptic therapy that can be missed if not suspected. This manuscript reviews the diagnosis and management of NMS in the primary care setting. There is a lack of prospective data, and most of the information is obtained from case series. Physicians need to have a high index of suspicion with regard to excluding NMS in patients taking neuroleptics and presenting with hyperthermia.
RESUMO
OBJECTIVE: To compare the effectiveness and tolerability of two hypnotic agents, trazadone (Desyrel) and zaleplon (Sonata) on psychiatric inpatients with insomnia. METHODS: Fifteen patients who were psychiatric inpatients were assigned openly and randomly to receive either trazodone (50-100 mg) or zaleplon (10-20 mg) doses on an "as-needed basis" and followed throughout their hospital stay. Efficacy and side effect profile were subsequently assessed. CONCLUSION: This pilot study suggests that trazodone may be a better agent to promote longer, deeper subjective quality sleep for psychiatric inpatients with insomnia in terms of effectiveness. However, tolerability was much better with zaleplon as daytime residual side effects were less.
Assuntos
Acetamidas/uso terapêutico , Hipnóticos e Sedativos/uso terapêutico , Transtornos Mentais/complicações , Pirimidinas/uso terapêutico , Inibidores Seletivos de Recaptação de Serotonina/uso terapêutico , Distúrbios do Início e da Manutenção do Sono/tratamento farmacológico , Trazodona/uso terapêutico , Administração Oral , Adolescente , Adulto , Idoso , Monitoramento de Medicamentos , Feminino , Humanos , Pacientes Internados , Masculino , Pessoa de Meia-Idade , Projetos Piloto , Estudos Prospectivos , Distúrbios do Início e da Manutenção do Sono/complicações , Distúrbios do Início e da Manutenção do Sono/diagnóstico , Fatores de Tempo , Resultado do TratamentoRESUMO
Weight gain is on the rise in the United States as is the diagnosis and treatment of mental disorders. These two phenomena are distinctly separate but tend to overlap in that most psychotropic agents approved for use in the United States are associated with the potential to induce weight gain. Metabolic disorders such as diabetes, hypercholesterolemia, and hypertension are also on the rise and often associated with weight gain and clearly associated with certain psychotropic medications. This article serves to provide a succinct review regarding the epidemiology, etiology, and treatment options for psychotropic-induced obesity.
Assuntos
Doenças Metabólicas/induzido quimicamente , Obesidade/induzido quimicamente , Obesidade/epidemiologia , Psicotrópicos/efeitos adversos , Peso Corporal/efeitos dos fármacos , Humanos , Estados Unidos/epidemiologiaRESUMO
A majority of psychiatric medications are known to generate weight gain and ultimately obesity in some patients. There is much speculation about the prevalence of weight gain and the degree of weight gain during acute and longitudinal treatment with these agents. There is newer literature looking at the etiology of this weight gain and the potential treatments being used to alleviate this side effect. The authors undertook a comprehensive literature review in order to present epidemiology, etiology, and treatment options of weight gain associated with antipsychotics, mood stabilizers, and antidepressants.
RESUMO
OBJECTIVE: An emerging adaptation of the assertive community treatment model is forensic assertive community treatment (FACT), which aims to prevent criminal recidivism. This study examined predictors of arrest among patients in a prototype program and considered the implications of study findings for future development of the FACT model. METHODS: Demographic and clinical data from all 130 patients treated in Project Link from 1997 through 2003 were merged with a statewide criminal record database to identify variables associated with arrest. RESULTS: Poisson regression revealed a history of arrests for violent offenses before treatment and evictions from residential treatment, and antisocial traits were associated with arrest during treatment. Substance abuse was not associated with arrest, but the sample lacked heterogeneity for this factor. CONCLUSIONS: Variables associated with arrest were similar to those seen in the general population. In the absence of a standardized model of intervention, FACT programs should incorporate interventions that target modifiable risk factors in order to prevent criminal recidivism among high-risk patients.
Assuntos
Psiquiatria Comunitária , Crime/prevenção & controle , Aplicação da Lei , Adulto , Feminino , Humanos , Masculino , New York , Distribuição de Poisson , Fatores de Risco , Prevenção SecundáriaRESUMO
In this article, we investigate the range of treatments prescribed for fibromyalgia. The data suggest that the majority of those treated, 72 percent, receive only one pharmaceutical. An additional 18 percent of patients were prescribed two products and 10% received three products. Pregabalin (Lyrica(R)) monotherapy was the most commonly prescribed regimen (28% of patients) followed by duloxetine (Cymbalta(R)) monotherapy (6%). From a therapeutic class perspective, fibromyalgia patients received pain therapies (42%), antiepileptics (40%), antidepressants (28%), muscle relaxants (14%), and sleep agents (8%). An expert commentary is also included.
RESUMO
BACKGROUND: The discovery of antidepressant medications has revolutionized the treatment of depression and other psychiatric illnesses. The coming of the selective serotonin (5-HT) reuptake inhibitors (SSRIs) marked a new era in the treatment of depression. These therapies frequently fall short of getting the patient to remission. Agents with a dual action have subsequently been developed which inhibit the reuptake of both 5-HT and NE, getting more patients to remission. Physical symptoms are associated with depression, preventing the patient from obtaining complete recovery. This article provides an overview of the pharmacology, efficacy, and techniques for the clinical use of duloxetine, a dual reuptake inhibitor, which has recently become available. METHODS: The English literature has been reviewed including both controlled and uncontrolled studies. RESULTS: Duloxetine is a dual reuptake inhibitor with actions on serotonin as well as norepinephrine. It has been shown to have efficacy in treating depressive symptoms including those with painful physical symptoms. Common side effects include nausea, insomnia, and dizziness. CONCLUSIONS: The article has been written with clinicians as the target audience, the data suggesting it can be used as a first line agent.
Assuntos
Antidepressivos/uso terapêutico , Transtorno Depressivo Maior/tratamento farmacológico , Tiofenos/uso terapêutico , Animais , Antidepressivos/efeitos adversos , Antidepressivos/farmacocinética , Ensaios Clínicos como Assunto , Transtorno Depressivo Maior/sangue , Transtorno Depressivo Maior/psicologia , Interações Medicamentosas , Cloridrato de Duloxetina , Meia-Vida , Humanos , Taxa de Depuração Metabólica , Dor/sangue , Dor/tratamento farmacológico , Dor/psicologia , Tiofenos/efeitos adversos , Tiofenos/farmacocinética , Resultado do TratamentoRESUMO
BACKGROUND: Diabetic ketoacidosis (DKA) has been associated with clozapine. The purpose of this study is to examine the clinical-demographic correlates of DKA among outpatients receiving clozapine. METHODS: A literature search was conducted from 1966 to present using Medline to identify 23 case reports of clozapine-associated DKA. In addition, a cohort of twenty-six patients with clozapine-associated diabetes at the University of Rochester Medical Center Department of Psychiatry were examined for histories of DKA through review of medical records. Based on a total sample of 26 case reports including three unpublished cases at University of Rochester, associations between clinical and demographic variables and DKA were examined. RESULTS: African American patients were significantly more likely than other patients to have DKA (p < 0.0001). Clozapine treatment duration was significantly shorter among patients with DKA than those without DKA (p < 0.0001), with 61.5% of patients developing DKA within three months of clozapine initiation. Also, presence of antidiabetic medications was negatively correlated with DKA (p < 0.0001). Trends were noted toward an association between low doses of clozapine (p < 0.0583) and toward a negative association between family history of diabetes (p < 0.0696). CONCLUSION: Clozapine is associated with DKA that usually presents in patients who have not previously been diagnosed with diabetes. DKA typically occurs early in the course of treatment, when clozapine treatment duration is short and doses are low.
Assuntos
Antipsicóticos/efeitos adversos , Clozapina/efeitos adversos , Cetoacidose Diabética/induzido quimicamente , Esquizofrenia/tratamento farmacológico , Adulto , Assistência Ambulatorial , Antipsicóticos/uso terapêutico , População Negra/psicologia , Clozapina/uso terapêutico , Estudos Transversais , Cetoacidose Diabética/diagnóstico , Cetoacidose Diabética/etnologia , Relação Dose-Resposta a Droga , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Fatores de Risco , Esquizofrenia/epidemiologia , Estatística como Assunto , População Branca/psicologiaRESUMO
GABA has been implicated in both the aetiology and treatment of anxiety. Tiagabine is currently the only selective GABA reuptake inhibitor available in US markets; it exerts its action via GAT-1 transporter blockade presynaptically, facilitating GABA neurotransmission. Preclinical studies and current human studies suggest tiagabine possesses anxiolytic properties. The anxiolytic properties of tiagabine have also been suggested in a number of case series, open-label studies and placebo-controlled studies in patients with different anxiety disorders. Throughout these studies, tiagabine has been reasonably tolerated; the most commonly reported adverse events include dizziness, headache and nausea. Tiagabine may be a useful addition to currently available drugs for anxiety; however, the data from small open-label investigations remain to be confirmed in larger controlled studies.
Assuntos
Transtornos de Ansiedade/tratamento farmacológico , Agonistas GABAérgicos/uso terapêutico , Ácidos Nipecóticos/uso terapêutico , Transtornos de Estresse Pós-Traumáticos/tratamento farmacológico , Feminino , Agonistas GABAérgicos/efeitos adversos , Agonistas GABAérgicos/farmacocinética , Humanos , Masculino , Ácidos Nipecóticos/efeitos adversos , Ácidos Nipecóticos/farmacocinética , Ensaios Clínicos Controlados Aleatórios como Assunto , Tiagabina , Ácido gama-Aminobutírico/fisiologiaRESUMO
UNLABELLED: This paper is a review article that collects and synthesizes up-to-date information about the complex etiological theories and treatment regimens associated with Fibromyalgia. The authors have written the paper in an evidence-based model in order to show the reader where adequate data exist in regards to these pharmacological, psychological, and physical strategies. A thorough MEDLINE search was utilized to collect many papers dedicated to this topic spanning 1970-2005. MEASUREMENTS: The relevant papers were divided, based upon intervention used for the treatment of FM (pharmacological vs. non-pharmacological). They were also divided based on their scientific merit; randomized controlled trials were given the most evidence-based weight and the case studies the least. RESULTS: The authors first review current epidemiologic and etiologic theories regarding fibromyalgia. A formal literature review is next presented to allow the reader to understand the evidence base that supports treatment of this disorder. In conclusion, a commentary regarding the treatment of this disorder in psychiatric practice occurs where pharmacodynamics and management strategy is discussed. CONCLUSION: There is much literature available regarding treatment of fibromyalgia. This complex illness has reasonable controlled studies for monotherapy treatments; however, multimodal treatments are the usual norm.
RESUMO
Personal attire is an important part of being a professional. This survey is an attempt to determine the patient's and psychiatrists view point about how a psychiatrist should dress to work. A human subjects research board approved survey of seven questions was offered to patients and a similar survey of nine questions was offered to psychiatrists. The replies obtained were combined and tabulated. One hundred patients and 77 psychiatrists responded to the survey. Both the patients and psychiatrists considered dress to be an important part of the doctor-patient relationship. The psychiatrists appear to be more concerned and critical about their dress as compared to patients.
Assuntos
Atitude do Pessoal de Saúde , Vestuário , Satisfação do Paciente , Psiquiatria , Adulto , Idoso , Atitude , Feminino , Pesquisas sobre Atenção à Saúde , Humanos , Masculino , Pessoa de Meia-Idade , Relações Médico-Paciente , Recursos HumanosRESUMO
BACKGROUND: At least 50% of patients with anxiety disorders experience only partial response to pharmacotherapy and require augmentation therapy. Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the CNS, and agents that modulate GABA neurotransmission have shown promise in the treatment of anxiety disorders and are often used as augmentation agents. OBJECTIVE: This study evaluated tiagabine, a selective GABA reuptake inhibitor (SGRI), as augmentation therapy. METHODS: This 8-week, open-label study enrolled patients who remained symptomatic despite adequate drug trials for treatment of anxiety symptoms. Tiagabine augmentation therapy was initiated at 4 mg/d (taken in 2 doses; one in the morning with breakfast and one in the evening with a snack) for 2 days and increased to 8 mg/d for 10 days. Dose was then adjusted according to efficacy/tolerability in increments of 2 mg every 3 days up to a maximum of 20 mg/d. Effect was assessed using the Hamilton Rating Scale for Anxiety (HAM-A), Beck Anxiety Inventory (BAI), Clinical Global Impression (CGI) scale, Pittsburgh Sleep Quality Index (PSQI), and 36-item Short-Form Health Survey (SF-36). RESULTS: Of the 18 patients enrolled, 17 were included in the efficacy analysis; one withdrew due to an adverse event prior to post-baseline assessment. Mean final dose of tiagabine was 13 mg/d. Tiagabine as augmentation therapy further reduced anxiety symptoms, as shown by significant decreases in mean HAM-A total and BAI scores at Week 8 (P<0.001). Thirteen patients (76%) responded (> or =50% reduction in HAM-A total score), and 10 patients (59%) achieved remission (HAM-A total score < or =7) at Week 8. Tiagabine improved sleep quality, with a significant reduction seen in PSQI global score at Week 8 (P=.001). Augmentation therapy with tiagabine was generally well tolerated. CONCLUSION: These preliminary findings suggest that the SGRI tiagabine may be an effective and generally well tolerated augmentation therapy in patients with anxiety who remain symptomatic despite adequate drug trials for treatment of anxiety symptoms.